185 related articles for article (PubMed ID: 29067565)
21. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
22. New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with (68)Ga(3.).
Ma MT; Cullinane C; Imberti C; Baguña Torres J; Terry SY; Roselt P; Hicks RJ; Blower PJ
Bioconjug Chem; 2016 Feb; 27(2):309-18. PubMed ID: 26286399
[TBL] [Abstract][Full Text] [Related]
23. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep.
Baur B; Solbach C; Andreolli E; Winter G; Machulla HJ; Reske SN
Pharmaceuticals (Basel); 2014 Apr; 7(5):517-29. PubMed ID: 24787458
[TBL] [Abstract][Full Text] [Related]
25. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.
Frigerio B; Benigni F; Luison E; Seregni E; Pascali C; Fracasso G; Morlino S; Valdagni R; Mezzanzanica D; Canevari S; Figini M
Immunol Lett; 2015 Nov; 168(1):105-10. PubMed ID: 26404855
[TBL] [Abstract][Full Text] [Related]
26. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer.
Han D; Wu J; Han Y; Wei M; Han S; Lin R; Sun Z; Yang F; Jiao D; Xie P; Zhang L; Yang AG; Zhao A; Wen W; Qin W
Oncotarget; 2016 Sep; 7(37):59471-59481. PubMed ID: 27448970
[TBL] [Abstract][Full Text] [Related]
27. The effects of trace metal impurities on Ga-68-radiolabelling with a tris(3-hydroxy-1,6-dimethylpyridin-4-one) (THP) chelator.
Cusnir R; Cakebread A; Cooper MS; Young JD; Blower PJ; Ma MT
RSC Adv; 2019 Nov; 9(64):37214-37221. PubMed ID: 35542301
[TBL] [Abstract][Full Text] [Related]
28. Hydroxypyridinone Chelators: From Iron Scavenging to Radiopharmaceuticals for PET Imaging with Gallium-68.
Cusnir R; Imberti C; Hider RC; Blower PJ; Ma MT
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075350
[TBL] [Abstract][Full Text] [Related]
29. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours.
Eder M; Knackmuss S; Le Gall F; Reusch U; Rybin V; Little M; Haberkorn U; Mier W; Eisenhut M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1397-407. PubMed ID: 20157706
[TBL] [Abstract][Full Text] [Related]
30. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
Parker SA; Diaz IL; Anderson KA; Batt CA
Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
[TBL] [Abstract][Full Text] [Related]
31. Anti-PSMA
Frigerio B; Morlino S; Luison E; Seregni E; Lorenzoni A; Satta A; Valdagni R; Bogni A; Chiesa C; Mira M; Canevari S; Alessi A; Figini M
J Exp Clin Cancer Res; 2019 Jul; 38(1):326. PubMed ID: 31337429
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.
Weineisen M; Simecek J; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2014 Dec; 4(1):63. PubMed ID: 26116124
[TBL] [Abstract][Full Text] [Related]
33. DATATOC: a novel conjugate for kit-type
Seemann J; Waldron B; Parker D; Roesch F
EJNMMI Radiopharm Chem; 2017; 1(1):4. PubMed ID: 29564381
[TBL] [Abstract][Full Text] [Related]
34. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
[TBL] [Abstract][Full Text] [Related]
35. Preclinical assessment of
Mandiwana V; Kalombo L; Lemmer Y; Labuschagne P; Semete-Makokotlela B; Sathekge M; Ebenhan T; Zeevaart JR
J Labelled Comp Radiopharm; 2019 Jun; 62(7):332-345. PubMed ID: 31054157
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
37.
Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
[TBL] [Abstract][Full Text] [Related]
38. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous
Eiber M; Weirich G; Holzapfel K; Souvatzoglou M; Haller B; Rauscher I; Beer AJ; Wester HJ; Gschwend J; Schwaiger M; Maurer T
Eur Urol; 2016 Nov; 70(5):829-836. PubMed ID: 26795686
[TBL] [Abstract][Full Text] [Related]
40.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
